New data from Antigen Express' ongoing Phase II study of the AE37 vaccine will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. Also, an oral abstract presentation followed by a discussion will be given focusing on Antigen Express' proprietory Ii-Key hybrid technology, which has been proven to greatly enhance the potency of CD4+ T helper cells.
AE37, an immunotherapeutic synthetic peptide vaccine to prevent relapse in patients who have had breast cancer, was most recently highlighted during a press conference organized by the American Association for Cancer Research, after a presentation titled "Immune Response Assessment in a Phase II Trial of AE37 HER2 Peptide Vaccine" by Dr. Diane F Hale. A press release from the AACR regarding that presentation can be found here.
On April 25th, ASCO unveiled the eplanner for their Annual Meeting, which opened the door to finding the titles of the new presentations. Full abstracts for the Annual Meeting will be available on ASCO's website after 6 pm on May 16th. Here is what we have learned so far:
Abstract #625
An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.
Diane F. Hale, MD, Poster Board: #12D
This poster will be presented during the "Breast Cancer - HER2/ER Sessions on June 2nd between 8:00 am and 12:00 pm in S Hall A2.
Abstract 2508
From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines
This is an oral abstract presentation being given by Timothy J Vreeland, with a discussion to folllow moderated by John Timmerman, MD. This highlighted event will be heard Monday, June 4th, during the "Developmental Therapeutics - Clinical Pharmacology and Immunotherapy" session held between 3:00 and 6:00 pm in the E Arie Crown Theater.
Be on the lookout for Generex, the parent company of Antigen Express, to provide more detailed updates as ASCO approaches.
